GO:0004957 prostaglandin E receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004957 (prostaglandin E receptor activity) describes the molecular function of receptors that bind prostaglandin E2 (PGE2) to initiate intracellular signaling.
• Four PGE2 receptor subtypes exist (EP1, EP2, EP3, and EP4), encoded by PTGER1, PTGER2, PTGER3, and PTGER4, each coupling to distinct G proteins.
• EP3 isoforms display constitutive Gi activity and agonist-dependent Gs activity, illustrating complex signaling plasticity.
• PGE2 receptor signaling is implicated in cancer immune evasion, cardiac ischemia/reperfusion injury, bone formation, and pancreatic beta-cell failure.
• EP4-specific antagonists are being explored in cancer immunotherapy to block immunosuppressive PGE2 signaling.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of PGE2 receptor function in disease contexts.
Description
Prostaglandin E receptor activity (GO:0004957) is a molecular function defined as the binding of prostaglandin E2 (PGE2) to a receptor, which then initiates a change in cell activity. This activity is mediated by a family of G protein-coupled receptors (GPCRs) known as EP receptors, comprising four subtypes: EP1, EP2, EP3, and EP4. Each subtype is encoded by a distinct gene (PTGER1, PTGER2, PTGER3, and PTGER4) and couples to different G protein alpha subunits, leading to diverse downstream signaling outcomes. The importance of this receptor activity spans immunology, cardiovascular biology, bone metabolism, and cancer, making it a focal point for both basic and translational research. Understanding the precise molecular mechanisms and regulatory nuances of PGE2 receptors is essential for developing targeted therapeutics.
prostaglandin E receptor activity At A Glance
| GO ID | GO:0004957 |
|---|---|
| GO term | prostaglandin E receptor activity |
| Ontology | molecular_function |
| Synonym | PGE(2) receptor activity; PGE receptor activity |
| Definition | Combining with prostaglandin E (PGE(2)) to initiate a change in cell activity. |
| Major function | Binding of PGE2 to initiate intracellular signaling via G protein-coupled receptors. |
| Receptor subtypes | EP1, EP2, EP3, EP4 (encoded by PTGER1, PTGER2, PTGER3, PTGER4). |
| G protein coupling | EP1 couples to Gq; EP2 and EP4 couple to Gs; EP3 primarily couples to Gi, with some isoforms showing Gs activity. |
| Tissue distribution | Widely expressed; prominent in immune cells, heart, bone, pancreatic islets, and reproductive tissues. |
What Is GO:0004957?
In simple terms, prostaglandin E receptor activity is the ability of a cell-surface receptor to recognize and bind prostaglandin E2 (PGE2), a lipid signaling molecule, and thereby trigger a cascade of events inside the cell. This activity is classified under the molecular function ontology because it describes a specific binding and signaling event at the molecular level. The receptors involved are seven-transmembrane GPCRs that, upon PGE2 binding, activate heterotrimeric G proteins, which then modulate enzymes such as adenylyl cyclase or phospholipase C, altering levels of second messengers like cAMP or calcium.
Why Is prostaglandin E receptor activity Important in Cell Biology?
Prostaglandin E receptor activity is critically important because PGE2 is one of the most abundant prostaglandins in the body and regulates diverse physiological and pathological processes, including inflammation, immune responses, cardiovascular homeostasis, bone remodeling, and cancer progression. Dysregulated PGE2 signaling contributes to diseases such as cancer, where it promotes immune evasion and tumor growth, and to cardiac injury following ischemia/reperfusion. Moreover, EP3 receptor isoforms exhibit constitutive activity and differential G protein coupling, adding layers of complexity that impact drug development. Thus, understanding this activity at the molecular level is essential for designing subtype-selective therapeutics.
• PGE2 receptor activity modulates immune responses and is a target for cancer immunotherapy.
• EP4 signaling in the heart influences ischemia/reperfusion injury and cardiac hypertrophy.
• EP3 receptor isoforms are implicated in pancreatic beta-cell failure and diabetes.
• PGE2 receptors regulate bone formation and remodeling, affecting osteoporosis.
• Constitutive Gi activity of EP3 isoforms affects basal cellular signaling.
• EP4-associated proteins can mediate anti-inflammatory signaling.
• PGE2 receptors are involved in inflammation and pain perception.
• Subtype-specific roles make them attractive for selective drug targeting.
• Genetic variations in PTGER genes may influence disease susceptibility.
• CRISPR models enable precise functional dissection of each receptor subtype.
Molecular Mechanism of prostaglandin E receptor activity
PGE2 Binding and Receptor Activation
In simple terms: PGE2 binds to the receptor like a key in a lock, causing the receptor to change shape and activate.
Prostaglandin E2 (PGE2) binds to the extracellular domain of EP receptors, inducing conformational changes that propagate through the seven-transmembrane domains to the intracellular face. This activation enables the receptor to act as a guanine nucleotide exchange factor for heterotrimeric G proteins.
G Protein Coupling and Subtype Specificity
In simple terms: Different EP receptors talk to different G proteins, leading to different cellular messages.
EP1 couples to Gq, activating phospholipase C and increasing intracellular calcium; EP2 and EP4 couple to Gs, stimulating adenylyl cyclase and raising cAMP; EP3 primarily couples to Gi, inhibiting adenylyl cyclase, though some isoforms can also activate Gs. This coupling diversity underlies the distinct physiological effects of each subtype.
Constitutive Activity of EP3 Isoforms
In simple terms: Some EP3 variants are always active, even without PGE2.
The EP3 receptor has multiple splice variants; EP3gamma exhibits mostly full constitutive Gi activity and agonist-dependent Gs activity. Another study showed that two EP3 isoforms differ in agonist-independent constitutive activity, influencing basal signaling. This constitutive activity can modulate cellular responses even in the absence of PGE2.
Regulation by Associated Proteins
In simple terms: Other proteins can bind to EP4 and change its signaling.
A novel EP4-associated protein was identified that participates in anti-inflammatory signaling, demonstrating that receptor activity can be modulated by interacting partners. This adds another layer of regulation beyond ligand binding and G protein coupling.
Downstream Signaling and Cellular Responses
In simple terms: Activation of EP receptors triggers changes in second messengers that alter cell behavior.
Depending on the subtype and cell type, PGE2 receptor activation can lead to increased cAMP, calcium mobilization, or inhibition of cAMP production, ultimately affecting gene expression, cell proliferation, migration, and survival. These downstream events are critical in inflammation, cancer, and cardiovascular disease.
Key Genes Involved in GO:0004957 prostaglandin E receptor activity
The following genes encode the receptors, enzymes, and associated proteins that mediate or regulate prostaglandin E receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGER1 | Encodes EP1 receptor; couples to Gq | Involved in pain, inflammation, and cancer |
| PTGER2 | Encodes EP2 receptor; couples to Gs | Roles in immune regulation, bone, and cancer |
| PTGER3 | Encodes EP3 receptor; multiple splice variants with Gi/Gs coupling | Implicated in pancreatic beta-cell failure and constitutive signaling |
| PTGER4 | Encodes EP4 receptor; couples to Gs | Target for cancer immunotherapy and cardiac injury |
| PTGS1 | Cyclooxygenase-1; produces prostaglandin precursors | Constitutive PGE2 synthesis |
| PTGS2 | Cyclooxygenase-2; inducible PGE2 synthesis | Inflammation and cancer |
| PTGES | Prostaglandin E synthase; converts PGH2 to PGE2 | Regulates PGE2 availability |
| GNAQ | Gq alpha subunit; mediates EP1 signaling | Downstream of EP1 |
| GNAS | Gs alpha subunit; mediates EP2/EP4 signaling | Downstream of EP2/EP4 |
| GNAI1 | Gi alpha subunit; mediates EP3 signaling | Downstream of EP3 |
| ARRB1 | Beta-arrestin 1; regulates GPCR desensitization | Modulates EP receptor signaling |
| ARRB2 | Beta-arrestin 2; regulates GPCR desensitization | Modulates EP receptor signaling |
| PRKACA | cAMP-dependent protein kinase A catalytic subunit | Mediates downstream effects of EP2/EP4 |
| CREB1 | cAMP response element-binding protein | Transcription factor activated by EP2/EP4 signaling |
| NFKB1 | Nuclear factor kappa B; inflammatory transcription factor | Cross-talk with PGE2 signaling |
| EP4RAP | EP4-associated protein; anti-inflammatory signaling | Modulates EP4 function |
How Is prostaglandin E receptor activity Regulated?
Prostaglandin E receptor activity is regulated at multiple levels. Ligand availability is controlled by the expression and activity of cyclooxygenases (PTGS1/PTGS2) and prostaglandin E synthases. Receptor desensitization and internalization are mediated by G protein-coupled receptor kinases and beta-arrestins. EP3 receptor activity is further regulated by alternative splicing, producing isoforms with distinct constitutive activities and G protein coupling. Additionally, EP4 can interact with associated proteins that modulate its signaling, as shown for a novel EP4-associated protein involved in anti-inflammatory pathways. These regulatory mechanisms fine-tune cellular responses to PGE2.
prostaglandin E receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGER4 | Cancer immune evasion | PTGER4 knockout in syngeneic tumor models |
| PTGER4 | Cardiac ischemia/reperfusion injury | Cardiac-specific PTGER4 knockout mice |
| PTGER3 | Pancreatic beta-cell failure | Beta-cell-specific PTGER3 isoform knockout |
| PTGER2 | Bone formation disorders | PTGER2 knockout osteoblast models |
| PTGER1 | Inflammation and pain | PTGER1 knockout in inflammatory pain models |
Cancer and Immune Evasion
PGE2 signaling through EP4 promotes an immunosuppressive tumor microenvironment, facilitating cancer immune evasion. EP4 antagonists are being developed to block this pathway and enhance anti-tumor immunity. Thus, prostaglandin E receptor activity is a key target in cancer immunotherapy.
Cardiovascular Disease
EP4 signaling in the heart plays a role in ischemia/reperfusion injury and cardiac hypertrophy. Modulation of EP4 activity may offer therapeutic benefits in cardiovascular diseases.
Diabetes and Beta-Cell Dysfunction
The EP3 receptor splice variant EP3-gamma is implicated in pancreatic beta-cell failure, contributing to diabetes pathogenesis. Posttranscriptional regulation of EP3-gamma affects beta-cell function.
Bone Disorders
PGE2 receptors regulate bone formation and resorption. Dysregulated signaling can lead to bone diseases such as osteoporosis.
From prostaglandin E receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EP4 affect tumor immune surveillance? | PTGER4 knockout mice or cancer cell lines |
| What is the role of EP3-gamma in beta-cell function? | PTGER3 isoform-specific knockout in pancreatic beta cells |
| How does EP4 signaling protect the heart? | Cardiac-specific PTGER4 overexpression or knockout |
| What is the effect of constitutive EP3 activity? | Point mutations mimicking constitutive activity |
| How does EP4-associated protein modulate signaling? | Knock-in of tagged EP4-associated protein |
| Which G protein couples to EP2 in bone cells? | G protein knockout or knockdown in osteoblasts |
How to Study the prostaglandin E receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and pathway components | Identify modifiers of PGE2 signaling |
| RNA-seq | Transcriptional changes | Map downstream effects of EP receptor activation |
| Proteomics | Protein interactions and abundance | Discover EP4-associated proteins |
| cAMP biosensor imaging | Intracellular cAMP dynamics | Measure EP2/EP4 activity in real time |
| Calcium imaging | Intracellular calcium flux | Measure EP1 activity |
| Western blot | Protein expression and phosphorylation | Assess downstream signaling |
| Immunohistochemistry | Tissue distribution of EP receptors | Localize receptors in disease tissues |
| Patch-clamp electrophysiology | Ion channel activity | Study EP receptor effects on excitability |
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes that modulate PGE2 receptor signaling, such as those affecting cell survival or immune evasion in cancer models.
Transcriptomics and RNA-seq
RNA sequencing reveals changes in gene expression downstream of PGE2 receptor activation, helping to map signaling networks and identify disease-relevant pathways.
Proteomics and Interactomics
Proteomic approaches can identify proteins associated with EP receptors, such as the EP4-associated protein involved in anti-inflammatory signaling.
Live-Cell Imaging and Biosensors
Genetically encoded cAMP or calcium biosensors enable real-time monitoring of PGE2 receptor activity in living cells, providing spatiotemporal insights.
How CRISPR Can Be Used to Study GO:0004957 prostaglandin E receptor activity
Knockout
CRISPR-Cas9 knockout of PTGER1, PTGER2, PTGER3, or PTGER4 in cell lines or animal models abolishes specific receptor activity, enabling assignment of subtype-specific functions in processes like immune evasion, cardiac injury, and beta-cell failure.
Point Mutation
Introducing point mutations that alter ligand binding or G protein coupling can dissect the contribution of specific residues to receptor activation. For example, mutations mimicking constitutive activity of EP3 isoforms help understand basal signaling.
Knock-in
Knock-in of tagged receptors (e.g., HA- or GFP-tagged EP4) allows visualization and immunoprecipitation of receptor complexes, facilitating the study of associated proteins and trafficking.
Overexpression
Overexpression of a specific EP receptor subtype in cell lines or transgenic animals can amplify signaling to study downstream effects, such as EP4-mediated cardioprotection or EP2-driven bone formation.
How EDITGENE Supports prostaglandin E receptor activity Research
Researchers studying prostaglandin E receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for prostaglandin E receptor activity research.
Frequently Asked Questions About prostaglandin E receptor activity
What is prostaglandin E receptor activity?
It is the molecular function of binding prostaglandin E2 (PGE2) to initiate intracellular signaling, mediated by EP receptors.
What genes are involved in prostaglandin E receptor activity?
The main genes are PTGER1, PTGER2, PTGER3, and PTGER4, encoding EP1, EP2, EP3, and EP4 receptors, respectively.
Which receptor subtypes bind PGE2?
Four subtypes: EP1, EP2, EP3, and EP4, each with distinct G protein coupling and tissue distribution.
How does EP4 signaling affect cancer?
EP4 signaling promotes immune evasion in tumors; EP4 antagonists are being tested in cancer immunotherapy.
What is the role of EP3 in diabetes?
The EP3-gamma isoform is implicated in pancreatic beta-cell failure, contributing to diabetes pathogenesis.
Can CRISPR be used to study PGE2 receptors?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies.
What diseases are linked to prostaglandin E receptors?
Cancer, cardiovascular disease, diabetes, and bone disorders are among the key diseases.
How is prostaglandin E receptor activity regulated?
It is regulated by ligand availability, receptor desensitization, alternative splicing, and interacting proteins.
What are the synonyms for GO:0004957?
PGE(2) receptor activity and PGE receptor activity.
What experimental models are used to study PGE2 receptors?
Knockout mice, point-mutant cell lines, tagged knock-in models, and overexpression systems.
Conclusion
Prostaglandin E receptor activity (GO:0004957) is a fundamental molecular function with broad implications in physiology and disease. The four EP receptor subtypes exhibit distinct signaling properties and tissue distributions, and their dysregulation contributes to cancer, cardiovascular disease, diabetes, and bone disorders. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate the precise mechanisms and enable targeted therapeutic development.
References
- 1. Take Y et al.. 2020. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.. Front Immunol 11:324 PMID: 32210957
- 2. Pang L et al.. 2016. Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac Hypertrophy.. J Diabetes Res 2016:1324347 PMID: 27190998
- 3. Srivastava R et al.. 2023. Posttranscriptional regulation of the prostaglandin E receptor spliced-isoform EP3-γ and its implication in pancreatic β-cell failure.. FASEB J 37(6):e22958 PMID: 37171267
- 4. Kawahara K et al.. 2015. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors.. Biochim Biophys Acta 1851(4):414-21 PMID: 25038274
- 5. Negishi M et al.. 1996. Prostaglandin E receptor EP3gamma isoform, with mostly full constitutive Gi activity and agonist-dependent Gs activity.. FEBS Lett 386(2-3):165-8 PMID: 8647273
- 6. Li M et al.. 2007. Prostaglandin E(2) receptors in bone formation.. Int Orthop 31(6):767-72 PMID: 17593365
- 7. Hasegawa H et al.. 1996. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity.. J Biol Chem 271(4):1857-60 PMID: 8567630
- 8. Takayama K et al.. 2006. A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling.. Circ Res 98(4):499-504 PMID: 16424369
